Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,550 | 4 | 72.1% |
| Unspecified | $4,078 | 4 | 25.4% |
| Food and Beverage | $395.09 | 6 | 2.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $15,628 | 8 | $0 (2024) |
| PALETTE LIFE SCIENCES, INC. | $174.39 | 1 | $0 (2021) |
| Varian Medical Systems, Inc. | $143.50 | 3 | $0 (2018) |
| Augmenix, Inc. | $77.20 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,200 | 2 | Neurocrine Biosciences, Inc. ($4,200) |
| 2023 | $7,350 | 2 | Neurocrine Biosciences, Inc. ($7,350) |
| 2022 | $1,453 | 2 | Neurocrine BioSciences, Inc. ($1,453) |
| 2021 | $2,799 | 3 | Neurocrine Biosciences, Inc. ($2,625) |
| 2018 | $99.19 | 3 | Augmenix, Inc. ($77.20) |
| 2017 | $121.51 | 2 | Varian Medical Systems, Inc. ($121.51) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/30/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 03/11/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 08/18/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| 03/17/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,975.00 | General |
| 10/19/2022 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $752.50 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 05/06/2022 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 12/02/2021 | PALETTE LIFE SCIENCES, INC. | DEFLUX (Device) | Food and Beverage | In-kind items and services | $174.39 | General |
| Category: URINARY | ||||||
| 11/04/2021 | Neurocrine Biosciences, Inc. | — | — | Cash or cash equivalent | $1,225.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 02/05/2021 | Neurocrine Biosciences, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 03/29/2018 | Varian Medical Systems, Inc. | TrueBeam (Device) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Devices | ||||||
| 03/27/2018 | Augmenix, Inc. | SpaceOAR (Device) | Food and Beverage | In-kind items and services | $63.90 | General |
| Category: Oncology | ||||||
| 02/16/2018 | Augmenix, Inc. | SpaceOAR (Device) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Oncology | ||||||
| 05/06/2017 | Varian Medical Systems, Inc. | — | Food and Beverage | In-kind items and services | $103.33 | General |
| 05/06/2017 | Varian Medical Systems, Inc. | — | Food and Beverage | In-kind items and services | $18.18 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine Biosciences, Inc. | $2,625 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $1,453 | 2 |
About Dr. David Diamond, MD
Dr. David Diamond, MD is a Medical healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619954658.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Diamond, MD has received a total of $16,023 in payments from pharmaceutical and medical device companies, with $4,200 received in 2024. These payments were reported across 14 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($11,550).
Practice Information
- Specialty Medical
- Other Specialties Urology
- Location Boston, MA
- Active Since 12/30/2005
- Last Updated 07/17/2023
- Taxonomy Code 363AM0700X
- Entity Type Individual
- NPI Number 1619954658
Products in Payments
- DEFLUX (Device) $174.39
- SpaceOAR (Device) $77.20
- TrueBeam (Device) $21.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Doctors in Boston
Mrs. Michelle Baytarian, Pa-C, PA-C
Medical — Payments: $17,033
Theresa Fukuda, Pa-C, PA-C
Medical — Payments: $9,623
Elissa Hokinson, Pa-C, PA-C
Medical — Payments: $5,751
Helen Le, P.a.-C, P.A.-C
Medical — Payments: $4,776
Jenna Daddario, Pa-C, PA-C
Medical — Payments: $4,513
Mr. William Mcneal, P.a.-C, P.A.-C
Medical — Payments: $2,415